Atlas Trials

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

Clinical trial NCT05060627 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05060627
Sponsor
PETHEMA Foundation
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed Multiple Myeloma
Start date
2021-12-20
Primary completion
2024-10-23
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.